Quanterix (QTRX) Stock
Small diagnostics maker with sensitive instruments for research. Here's the price, business snapshot, and what's worth knowing about Quanterix in October 2026.
Quanterix Corporation (QTRX) is a small-cap diagnostics company that makes ultra-sensitive immunoassay instruments and assays under its Simoa (single molecule array) platform. Investors should know Quanterix sells analytical instruments and consumable assays used by research labs and clinical partners to detect low-abundance biomarkers across neurology, oncology and other fields. The business model mixes instrument sales with recurring reagent and service revenues, but growth depends on broader clinical adoption of its assays, partnership deals, and continued product development. With a market cap near $281.6m, the company faces typical biotech and device risks — regulatory hurdles, competition from incumbent laboratory platforms, and periodic capital needs. Potential upside comes from expanded clinical use, higher reagent attach rates and new assays, while performance can be volatile and past performance is not a guide to future returns. This is general educational information, not personalised investment advice.
Quanterix (QTRX) Stock Forecast
Analyst price target, next 12 months
$12.38
+240.0% vs today's $3.64
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Quanterix have a consensus 12-month target of $12.38, above the current price of $3.64.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend holding Quanterix's stock with a target price of $12.38, indicating potential growth.
Financial Health
Quanterix Corporation is showing strong revenue and cash flow, with a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Recurring revenue potential
Instrument sales can lead to steady consumable and reagent revenue, which may support long-term growth — though recurring sales can vary with adoption rates.
Clinical adoption focus
Wider use of Simoa assays in neurology and oncology could expand addressable markets, but adoption depends on regulatory approval and clinician uptake.
Technology edge
Ultra‑sensitive single-molecule detection differentiates the platform; however, competition and execution risks mean outcomes can be uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
